secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001140361-25-029582
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharmaceuticals: President Patel to depart, 30% workforce cut, Q2 net loss $68.9M
--------------------------------------------------------------------------------

- Dr. Kinnari Patel to leave as President and Head of R&D effective Dec 31, 2025; steps down Aug 8.
- Workforce reduction of ~30% and cash burn cut ~25% as part of strategic restructuring.
- Q2 net loss $68.9M ($0.62/share); cash $271.5M; expects runway into Q2 2027.
- Clinical hold on RP-A501 Danon disease trial ongoing after patient death; engaging with FDA.
- Chris Stevens appointed COO in July; former Spark Therapeutics executive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125029582/0001140361-25-029582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125029582/ef20053509_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-029582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer